NeoStem (AMEX: NBS) Q3/11 and 9 Month Results
Net loss attributable to NBS for Q3/11 was $7.97M or $0.08 per share, compared to a net loss of $7.14M or $0.13 per share for Q3/10.
Revenue for Q3/11 was $17.756M, up from $16.475M for Q3/10. R&D expenses were $2.48M; G&A was $8.81M for total expenses of $11.295M and a loss from operations of $7.38M. Other income (expense) was $78K. Weighted average of common shares (outstanding basic and diluted) attributable was 94.1M.
- Cash and cash equivalents totaled $11.7M, restricted cash of $1.42M and account receivable of $8.9M as of 9/30/11
For the 9 months ended 9/30/11: Total revenues were $55.857M with a cost of revenues of $41.63M while R&D logged in at $7.76M and SG&A was $31.8M for total operating expenses of $39.595M with an operating loss from operations of $25.37M. The net loss was approximately $28.28M or $0.35 per share, compared to net loss of $17.27M or $0.36 per share for the same period of 2010. Revenue was $55.857M, compared to $51.716 M in the same period of 2010. Weighted average of common shares (outstanding basic and diluted) attributable was 82.77M versus 48.59M in the same period in 2010.